Key result
Bleomycin acts primarily by inhibiting DNA synthesis across multiple sulfur-containing polypeptide fractions.
Why the study?
Bleomycin was recently approved by the Food and Drug Administration for widespread clinical use following extensive joint evaluation.
Following extensive, joint evaluation by the National Cancer Institute and the Bristol Laboratories Division of Bristol Myers Company, bleomycin has re cently been approved by the Food and Drug Administration for widespread use. Originally isolated from Strepto myces verticillus by Umezawa in Japan,1'2 bleomycin is composed of sul fur-containing polypeptides that sepa rate by paper chromatography into two large fractions and 11 subfractions. Available evidence suggests that bleo mycin acts primarily by inhibiting DNA synthesis and, to a lesser extent, RNA and protein synthesis.
No takes yet. Share an insight, caveat, or question.
Carter et al. (1974) conducted a review in Cancer. Bleomycin and Adriamycin was evaluated. Bleomycin, composed of 2 large fractions and 11 subfractions of sulfur-containing polypeptides, acts primarily by inhibiting DNA synthesis and has received FDA approval.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: